--- title: "Viridian Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy Rating" description: "Rami Katkhuda has rated Viridian Therapeutics as a Buy due to promising developments in its pipeline, particularly VRDN-003, which has completed enrollment in the pivotal REVEAL program for Thyroid Ey" type: "news" locale: "en" url: "https://longbridge.com/en/news/257398994.md" published_at: "2025-09-15T14:35:22.000Z" --- # Viridian Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy Rating > Rami Katkhuda has rated Viridian Therapeutics as a Buy due to promising developments in its pipeline, particularly VRDN-003, which has completed enrollment in the pivotal REVEAL program for Thyroid Eye Disease. The potential for a Biologics License Application submission by next year, along with a new patent for VRDN-003 and the anticipated launch of veligrotug in 2026, supports this rating. Katkhuda, a 5-star analyst, has a 30.7% average return and a 53.33% success rate. Wedbush also maintains a Buy rating with a $40 price target. Rami Katkhuda’s rating is based on several promising developments within Viridian Therapeutics’ pipeline, particularly the progress of VRDN-003. The completion of enrollment in the pivotal REVEAL program, which assesses the safety and efficacy of VRDN-003 in both active and chronic Thyroid Eye Disease (TED), is a significant milestone. The studies not only exceeded their enrollment targets but also have the potential to lead to a Biologics License Application (BLA) submission by the end of next year if the upcoming data is positive. This progress, combined with the drug’s advantageous properties, such as its formulation as a low-volume, self-administered autoinjector, positions VRDN-003 favorably in the TED market. Additionally, the recent granting of a composition of matter patent for VRDN-003, valid until 2041, strengthens Viridian’s intellectual property portfolio. The anticipation of a BLA submission for veligrotug, another promising candidate, with a potential commercial launch in mid-2026, further supports the Buy rating. The Breakthrough Therapy Designation granted by the FDA underscores veligrotug’s rapid and significant clinical benefits, enhancing its differentiation from existing therapies. These factors collectively indicate a strong growth potential for Viridian Therapeutics, justifying the Buy recommendation. According to TipRanks, Katkhuda is a 5-star analyst with an average return of 30.7% and a 53.33% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as VYNE Therapeutics, Dianthus Therapeutics, and Mineralys Therapeutics, Inc.. In another report released today, Wedbush also maintained a Buy rating on the stock with a $40.00 price target. ### Related Stocks - [VRDN.US - Viridian Therapeutics](https://longbridge.com/en/quote/VRDN.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | FDA 接受了 Viridian Therapeutics 的 Veligrotug 生物製劑許可申請，並將進行優先審查 | Viridian Therapeutics Inc. 宣佈，FDA 已接受其針對 veligrotug 的生物製品許可申請，並將其列為優先審查，用於治療甲狀腺眼病。PDUFA 決策目標日期為 2026 年 6 月 30 日，預計在 2026 | [Link](https://longbridge.com/en/news/271647218.md) | | FDA 對 Veligrotug 的優先審查如何重塑 Viridian Therapeutics（VRDN）的甲狀腺眼病投資故事 | Viridian Therapeutics 已獲得 FDA 對其生物製劑許可申請 veligrotug 的優先審查，目標是治療甲狀腺眼病，預計將在 2026 年 6 月 30 日之前做出決定。這一進展預計將增強公司的投資敍事，儘管由於其尚未 | [Link](https://longbridge.com/en/news/271759584.md) | | 隨着公司推進更優越的 ALS 療法，Coya Therapeutics 的股票有望升值 | Coya Therapeutics (COYA) 是一家臨牀階段的生物科技公司，正在推進其主要候選藥物 COYA 302，用於治療肌萎縮側索硬化症（ALS）和額顳葉痴呆（FTD），該藥物利用低劑量白介素-2 來對抗神經炎症。公司與 Dr. | [Link](https://longbridge.com/en/news/275894413.md) | | FDA 對 Veli 治療甲狀腺眼病的審查可能會改變投資 Viridian Therapeutics（VRDN）的理由 | 高盛和 Needham 的分析師重申了對 Viridian Therapeutics 的積極看法，此前該公司向 FDA 提交了其甲狀腺眼病療法 veli 的生物製品許可申請。FDA 對 veli 的審查可能會重塑市場對 Viridian 稀 | [Link](https://longbridge.com/en/news/270386575.md) | | REGENXBIO 宣佈關於 RGX-121 用於 MPS II 的生物製品許可申請的監管進展 | Regenxbio Inc：Regenxbio 宣佈關於 RGX-121 的 MPS II BLA 的監管更新 Regenxbio Inc - FDA 對 RGX-121 發出完整回應函 Regenxbio Inc - 計劃重新提交 RGX | [Link](https://longbridge.com/en/news/275367329.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.